The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history
Open accessAbstract
PurposePanel-based genetic testing has identified increasing numbers of patients with pancreatic ductal adenocarcinoma (PDAC) who carry germ-line mutations. However, small sample sizes or number of genes evaluated limit prevalence estimates of these mutations. We estimated prevalence of mutations in PDAC patients with positive family history.MethodsWe sequenced 25 cancer susceptibility genes in lymphocyte DNA from 302 PDAC patients in the Mayo Clinic Biospecimen Resource for Pancreatic Research Registry. Kindreds containing at least two first-degree relatives with PDAC met criteria for familial pancreatic cancer (FPC), while the remaining were familial, but not FPC.ResultsThirty-six patients (12%) carried at least one deleterious mutation in one of 11 genes. Of FPC patients, 25/185 (14%) were carriers, while 11/117 (9%) non-FPC patients with family history were carriers. Deleterious mutations (n) identified in PDAC patients were BRCA2 (11), ATM (8), CDKN2A (4), CHEK2 (4), MUTYH/MYH (3 heterozygotes, not biallelic), BRCA1 (2), and 1 each in BARD1, MSH2, NBN, PALB2, and PMS2. Novel mutations were found in ATM, BARD1, and PMS2.ConclusionMultiple susceptibility gene testing in PDAC patients with family history of pancreatic cancer is warranted regardless of FPC status and will inform genetic risk counseling for families.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Deleterious variants in the known pancreatic cancer susceptibility genes account for ~10–20% of the familial clustering of pancreatic cancer.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Syngal, S., Brand, R. E., Church, J. M., Giardiello, F. M., Hampel, H. L., & Burt, R. W. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.435 · Cited by 1,662
Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors
Tassan, N. A. A., Chmiel, N. H., Maynard, J. H., Fleming, N. I., Livingston, A. L., Williams, G. T., Hodges, A., Davies, D. R., David, S. S., Sampson, J. R., et al. (2002) · Nature Genetics · doi:10.1038/ng828 · Cited by 1,408
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., Lin, J. C.-H., Palmisano, E., Brune, K., Jaffee, E. M., et al. (2009) · Science · doi:10.1126/science.1171202 · Cited by 826 · cited 13×
“Twenty-seven individuals were found to carry a PV in a gene associated with increased risk of breast cancer (ATM, BARD1, BRCA1, BRCA2, CHEK2, PALB2, NBN).”
InfluentialLocalization of an ataxia-telangiectasia gene to chromosome 11q22–23
Gatti, R. A., Berkel, İ., Boder, E., Braedt, G., Charmley, P., CONCANNON, P. J., Ersoy, F., Foroud, T., Jaspers, N. G. J., Lange, K. L., et al. (1988) · Nature · doi:10.1038/336577a0 · Cited by 684
Genetic/Familial High-Risk Assessment: Breast and Ovarian
Daly, M. B., Axilbund, J. E., Buys, S. S., Crawford, B., Farrell, C. D., Friedman, S., Garber, J. E., Goorha, S., Gruber, S. B., Hampel, H., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0043 · Cited by 646
Tung, N., Lin, N., Kidd, J., Allen, B. A., Singh, N., WENSTRUP, R. J., Hartman, A., Winer, E. P., & Garber, J. E. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.0747 · Cited by 580
Self-citationCHEK2 Is a Multiorgan Cancer Susceptibility Gene
Cybulski, C., Górski, B., Huzarski, T., Masojć, B., Mierzejewski, M., Dębniak, T., Teodorczyk, U., Byrski, T., Gronwald, J., Matyjasik, J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/426403 · Cited by 560
Risk of Pancreatic Cancer in Families With Lynch Syndrome
Kastrinos, F. (2009) · JAMA · doi:10.1001/jama.2009.1529 · Cited by 544
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–143 of 143
Inherited predisposition to pancreatic cancer
Hilfrank, K. J., Rustgi, S. D., & Kastrinos, F. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.006 · Cited by 3
Lin, P., Tien, Y., Cheng, W., Chiang, Y., Wu, C., Yang, K., & Huang, C. (2023) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2023.34.e66 · Cited by 3
Darabi, S., Homer, J. P., Torres, C. B., Zuazo, C. E., Dalili-Shoaie, V., Demeure, M. J., & Braxton, D. R. (2024) · Oncology Issues · doi:10.3928/25731777-20240806-08 · Cited by 3
Familial pancreatic cancer: who should be considered for genetic testing?
Kartal, K., Guan, Z., Tang, R., Griffin, M., Wang, Y., Braun, D., Klein, A. P., & Hughes, K. S. (2021) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02572-9 · Cited by 3
Progress report: familial pancreatic cancer
Mintziras, I., & Bartsch, D. K. (2019) · Familial Cancer · doi:10.1007/s10689-019-00125-9 · Cited by 3
KRAS-Wild Pancreatic Cancer—More Targets than Treatment Possibilities?
Krupa, K., Fudalej, M. M., Miski, H., Włoszek, E., Szymczak, M., Badowska-Kozakiewicz, A. M., Czerw, A. I., & Deptała, A. (2025) · Cancers · doi:10.3390/cancers17233769 · Cited by 2
Prospects of PARP Inhibitors in Treatment of BRCA-Mutated Pancreatic Cancer: a Literature Review
Меньшиков, К. В., Султанбаев, А. В., Мусин, Ш. И., Измайлов, А. А., Menshikovа, I. A., Султанбаева, Н. И., Popova, E. V., & Хамматова, Л. А. (2022) · Creative Surgery and Oncology · doi:10.24060/2076-3093-2022-12-1-48-55 · Cited by 2
Prospective Screening of Cancer Syndromes in Patients with Mesenchymal Tumors
Öfverholm, I. I., Lin, Y., Mondini, J., Hardingz, J., Bränström, R., Tsagozis, P., Wirta, V., Gellerbring, A., Lindberg, J., Chellappa, V., et al. (2024) · Cancers · doi:10.3390/cancers16223816 · Cited by 2
Surveillance Outcome and Genetic Findings in Individuals at High Risk of Pancreatic Cancer
Rosner, G., Scapa, E. F., Ziv, T., Gluck, N., & Ben‐Yehoyada, M. (2023) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000668 · Cited by 2
BARD1: A Friend or Foe in Pancreatic Ductal Adenocarcinoma?
Zekavat, L., & Jain, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189041 · Cited by 1
Germline variant spectrum of hereditary cancer susceptibility genes in a Chinese cohort
Xiong, C., Wang, X., Ji, J., Yu, T., Zhang, Y., Jiang, Z., Liu, J., Zhang, J., Yin, L., Gong, B., et al. (2025) · Human Genomics · doi:10.1186/s40246-025-00873-z · Cited by 1
Arif, S., Muhammad, N., Naeemi, H., & Rashid, M. U. (2025) · Familial Cancer · doi:10.1007/s10689-025-00515-2 · Cited by 1
Hereditary Syndromes and Pancreatic Cancer
Pölsler, L., Claes, K., & Zschocke, J. (2021) · Springer eBooks · doi:10.1007/978-3-030-53786-9_3 · Cited by 1
Characteristics of familial pancreatic cancer families with additional colorectal carcinoma
Lehman, B., Matthäi, E., Krasser‐Gercke, N., Denzer, U. W., Figiel, J. H., Hess, T., Slater, E. P., & Bartsch, D. K. (2023) · Familial Cancer · doi:10.1007/s10689-023-00328-1 · Cited by 1
Cristina-Marianini-Rios, Sanchez, M. E. C., de Paredes, A. G. G., Rodríguez, M., Barreto, E., López, J. V., Fuentes, R., Beltrán, M. M., Sanjuánbenito, A., Lobo, E., et al. (2024) · Familial Cancer · doi:10.1007/s10689-024-00397-w · Cited by 1
Kimura, H., Lahouel, K., Tomasetti, C., & Roberts, N. J. (2024) · eLife · doi:10.7554/elife.95347.4 · Cited by 5
Statistical approaches for meta‐analysis of genetic mutation prevalence
Hujoel, M. L. A., Parmigiani, G., & Braun, D. (2020) · Genetic Epidemiology · doi:10.1002/gepi.22364 · Cited by 1
Familial Predisposition and Genetic Risk Factors Associated with Pancreatic Cancer
Rustgi, S. D., Hilfrank, K. J., & Kastrinos, F. (2021) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2021.09.001 · Cited by 1
Whole genome sequencing identifies rare genetic variants in familial pancreatic cancer patients
Tan, M., Brusgaard, K., Gerdes, A., Larsen, M. J., Mortensen, M. B., Detlefsen, S., de Muckadell, O. B. S., & Jøergensen, M. T. (2022) · Annals of Human Genetics · doi:10.1111/ahg.12464 · Cited by 1
Screening of Patients with Hereditary Pancreatic Cancer
Goggins, M. (2018) · Wiley eBooks · doi:10.1002/9781119188421.ch98
Genetic Counseling for Pancreatic Cancer
Geurts, J. L. (2019) · Springer eBooks · doi:10.1007/978-3-319-98944-0_13
Reducing the Risk of and Screening for Pancreatic Cancer
Kothari, S., Kaul, V., & Kothari, T. H. (2021) · Springer eBooks · doi:10.1007/978-3-030-37482-2_35-1
The Poly(ADP-ribose) polymerase inhibitors in pancreatic cancer
Zubik, K., Talaśka, J., Sigorski, D., & Nawrocki, S. (2022) · Nowotwory Journal of Oncology · doi:10.5603/njo.2022.0004
Roberts, N. J., & Wood, L. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-53786-9_4
Germline Testing for Individuals with Pancreatic Adenocarcinoma and Novel Genetic Risk Factors
Chittenden, A. B., Haraldsdóttir, S., Chen, E., & Nissim, S. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.07.008
Reducing the Risk of and Screening for Pancreatic Cancer
Kothari, S., Kaul, V., & Kothari, T. H. (2022) · Springer eBooks · doi:10.1007/978-3-030-41683-6_35
Ductal Adenocarcinoma and Pancreatic Intraepithelial Neoplasia
(2023) · American Registry of PathologyArlington, Virginia eBooks · doi:10.55418/9781933477275-07
Furniss, C. S., Yurgelun, M. B. B., Ukaegbu, C. I., Constantinou, P. E., Lafferty, C. C., Talcove-Berko, E. R., Schwartz, A., Stopfer, J. E., Underhill-Blazey, M. L., Kenner, B. J., et al. (2023) · doi:10.1158/1940-6207.c.6547129.v1
Self-citationFurniss, C. S., Yurgelun, M. B. B., Ukaegbu, C. I., Constantinou, P. E., Lafferty, C. C., Talcove-Berko, E. R., Schwartz, A., Stopfer, J. E., Underhill-Blazey, M. L., Kenner, B. J., et al. (2023) · doi:10.1158/1940-6207.c.6547129
Self-citationKatona, B. W., Long, J. M., Ahmad, N. A., Attalla, S., Bradbury, A. R., Carpenter, E. L., Clark, D. F., Constantino, G., Das, K. K., Domchek, S. M., et al. (2023) · doi:10.1158/1940-6207.c.6547030
Hall, M. J., Bernhisel, R., Hughes, E., Larson, K., Rosenthal, E. T., Singh, N. A., Lancaster, J. M., & Kurian, A. W. (2023) · doi:10.1158/1940-6207.22534658
Self-citationZhong, Y., Zhang, H., Wang, P., Zhao, J., Ge, Y., Sun, Z., Wang, Z., Li, J., & Hu, S. (2024) · Investigational New Drugs · doi:10.1007/s10637-024-01454-y · Cited by 1
Hijioka, S., Morizane, C., & Okusaka, T. (2024) · Suizo · doi:10.2958/suizo.39.215
Roldan‐Vasquez, E., Cohen, S. M., & Kent, T. S. (2025) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.05.004
Predictive Clinical Features in Germline Testing for Renal Cell Carcinoma
Rompré‐Brodeur, A., Gopal, N., Millan, B., Owens-Walton, J., Webster, B. R., Daneshvar, M., Gurram, S., Nielsen, D., Ryan, B., Choo, K., et al. (2025) · Urology · doi:10.1016/j.urology.2025.07.035
Deciphering genetic susceptibility to clear cell renal cell carcinoma
Mandelia, M., Law, P., Mills, C., Went, M., Vijayakrishnan, J., & Houlston, R. S. (2025) · Communications Biology · doi:10.1038/s42003-025-09297-w
Lin, R.-T., Chen, P.-L., Yang, C.-Y., Yeh, C.-C., Lin, C.-C., Huang, W.-H., Chung, A.-K., & Lin, J.-T. (2022) · Figshare · doi:10.6084/m9.figshare.19768117
Lin, R.-T., Chen, P.-L., Yang, C.-Y., Yeh, C.-C., Lin, C.-C., Huang, W.-H., Chung, A.-K., & Lin, J.-T. (2022) · Figshare · doi:10.6084/m9.figshare.19768114
Сергеевна, П. Н., Bolotina, L. V., Kornietskaya, A. L., & Физулиевна, Е. С. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-515
Abdel‐Razeq, H., Saleh, Y., Hani, H. B., Abdel-Razeq, R. H., Mohamad, I., Sharaf, B., Tamimi, F., Abu-Jaish, H., Al-Atary, A., Aljabri, A., et al. (2026) · BMC Cancer · doi:10.1186/s12885-026-15669-0
Dzikowski, M. M., Pollin, G., Gunia, V., Butler, S., Enkhtuul, B., Chavez, J. G., Zimmermann, M. T., Mathison, A., Urrutia, R. A., & Lomberk, G. A. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1748541
Levinson, E. J., Hilfrank, K., Rustgi, S., & Kastrinos, F. (2026) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2026.07.002
Buono, A. D., Poliani, L., Greco, L., Bianchi, P., Barile, M., Giatti, V., Bonifacio, C., Carrara, S., Malesci, A., & Laghi, L. (2023) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.10039427
Metadata
- Authors
- Chaffee, K. G., Oberg, A. L., McWilliams, R. R., Majithia, N., Allen, B. A., Kidd, J., Singh, N., Hartman, A.-R., Wenstrup, R. J., & Petersen, G. M.
- Affiliations
- Mayo Clinic (US)
- Myriad Genetics (US)
- Corresponding author
- Petersen, Gloria M.
- ORCID
- Venue
- Genetics in Medicine
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 20
- Issue
- 1
- Pages
- 119-127
- ISSN
- 1098-3600 (ISSN-L)
- PMC
- PMC5760284
- OpenAlex
- W2738571634
- Cited by
- 144
- References
- 38
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 15 · 2023: 23 · 2022: 19 · 2021: 34 · 2020: 14 · 2019: 10 · 2018: 9
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Genetics in Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (CA102701)
- National Cancer Institute (CA102701, R01CA-97075, P50CA102701, R01CA097075)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- pancreatic ductal adenocarcinoma, germline mutations, cancer susceptibility genes, familial pancreatic cancer, family history (medicine), mutation prevalence, BRCA2, ATM, CDKN2A, CHEK2, MUTYH, BARD1, PMS2, novel mutations
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alleles, Carcinoma, Female, Genetic Testing, Genotype, Humans, Male, Middle Aged, Pancreatic Neoplasms, Registries, United States, Prevalence, Germ-Line Mutation, Genetic Predisposition to Disease, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
